Targeting Gonadotropin-releasing Hormone Receptor Inhibits the Early Step of Ovarian Cancer Metastasis by Modulating Tumor-mesothelial Adhesion

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2012 Nov 21

PMID 23164934

Citations 12

Authors

Lydia W T Cheung

Susan Yung

Tak-Mao Chan

Peter C K Leung

Alice S T Wong

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer has a clear predilection to metastasize to the peritoneum, which represents one of the most important prognostic factors of poor clinical outcome. Gonadotropin-releasing hormone (GnRH) receptor is significantly overexpressed during the malignant progression of human ovarian cancer. Here, using lentiviral-based small interfering RNA (siRNA) technology to downregulate GnRH receptor in metastatic ovarian cancer cells, we show that GnRH receptor is an important mediator of ovarian cancer peritoneal metastasis. GnRH receptor downregulation dramatically attenuated their adhesion to the peritoneal mesothelium. By inhibiting the expression of GnRH receptor, we showed decreased expression of α2β1 and α5β1 integrin and adhesion to specific extracellular matrix (ECM) proteins. This was also associated with a reduction of P-cadherin. Furthermore, adhesion of ovarian cancer cells to different ECMs and the mesothelium were abrogated in response to β1 integrin and P-cadherin reduction, confirming that the effects were β1 integrin- and P-cadherin-specific. Using a mouse model of human ovarian cancer metastasis, we found that the inhibition of GnRH receptor, β1 integrin, and P-cadherin significantly attenuated tumor growth, ascites formation, and the number of metastatic implants. These results define a new role for GnRH receptor in early metastasis and offer the possibility of novel therapeutic targets.

Citing Articles

Anticancer and Biological Effects of Some Natural Compounds and Theoretical Investigation of them Against RdRP of SARS-COV-2: In Silico and In Vitro Studies.

Zhang J, Feng J, Li Y, Wang J, Mo P, Luo C Mol Biotechnol. 2023; 65(11):1764-1776.

PMID: 36780057 PMC: 9923641. DOI: 10.1007/s12033-023-00678-2.

Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer.

Pereira M, Matuszewska K, Jamieson C, Petrik J Front Endocrinol (Lausanne). 2021; 12:772349.

PMID: 34867818 PMC: 8635771. DOI: 10.3389/fendo.2021.772349.

PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via α5β1 integrin and JNK/IL-8 signaling.

Siu M, Jiang Y, Wang J, Leung T, Ngu S, Cheung A Oncogenesis. 2020; 9(2):24.

PMID: 32071289 PMC: 7028730. DOI: 10.1038/s41389-020-0209-0.

Age at menarche and epithelial ovarian cancer risk: A meta-analysis and Mendelian randomization study.

Yang H, Dai H, Li L, Wang X, Wang P, Song F Cancer Med. 2019; 8(8):4012-4022.

PMID: 31145551 PMC: 6639189. DOI: 10.1002/cam4.2315.

Krüppel like factor 6 splice variant 1 (KLF6-SV1) overexpression recruits macrophages to participate in lung cancer metastasis by up-regulating TWIST1.

Wang J, Wang X, Wang Y, Li S, Wang X Cancer Biol Ther. 2018; 20(5):680-691.

PMID: 30590988 PMC: 6605981. DOI: 10.1080/15384047.2018.1550570.

References

Sundfeldt K . Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol. 2003; 202(1-2):89-96. DOI: 10.1016/s0303-7207(03)00068-6. View

Comoglio P, Boccaccio C, Trusolino L . Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr Opin Cell Biol. 2003; 15(5):565-71. DOI: 10.1016/s0955-0674(03)00096-6. View

Schmidmaier R, Baumann P . ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem. 2008; 15(10):978-90. DOI: 10.2174/092986708784049667. View

Zhu G, Risteli J, Puistola U, Kauppila A, Risteli L . Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. Cancer Res. 1993; 53(20):5028-32. View

Gardner M, Jones L, Catterall J, Turner G . Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett. 1995; 91(2):229-34. DOI: 10.1016/0304-3835(95)03743-g. View

Verschraegen C, Westphalen S, Hu W, Loyer E, Kudelka A, Volker P . Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2003; 90(3):552-9. DOI: 10.1016/s0090-8258(03)00408-6. View

Patel I, Madan P, Getsios S, Bertrand M, Maccalman C . Cadherin switching in ovarian cancer progression. Int J Cancer. 2003; 106(2):172-7. DOI: 10.1002/ijc.11086. View

Yung S, Li F, Chan T . Peritoneal mesothelial cell culture and biology. Perit Dial Int. 2006; 26(2):162-73. View

Chen N, Hasan T . Integrin-mediated adhesion and signalling in ovarian cancer cells. Cell Signal. 1998; 10(1):55-63. DOI: 10.1016/s0898-6568(97)00074-0. View

10.

Harvey W, Amlot P . Collagen production by human mesothelial cells in vitro. J Pathol. 1983; 139(3):337-47. DOI: 10.1002/path.1711390309. View

11.

Cheung L, Mak A, Cheung A, Ngan H, Leung P, Wong A . P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin. Oncogene. 2011; 30(26):2964-74. DOI: 10.1038/onc.2011.7. View

12.

Cheung L, Leung P, Wong A . Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. Oncogene. 2010; 29(16):2427-40. DOI: 10.1038/onc.2009.523. View

13.

Wong A, Maines-Bandiera S, Rosen B, Wheelock M, Johnson K, Leung P . Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Int J Cancer. 1999; 81(2):180-8. DOI: 10.1002/(sici)1097-0215(19990412)81:2<180::aid-ijc3>3.0.co;2-7. View

14.

Ahmed N, Riley C, Rice G, Quinn M . Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis. 2005; 22(5):391-402. DOI: 10.1007/s10585-005-1262-y. View

15.

Irmer G, Burger C, Muller R, Ortmann O, Peter U, Kakar S . Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res. 1995; 55(4):817-22. View

16.

Naora H, Montell D . Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005; 5(5):355-66. DOI: 10.1038/nrc1611. View

17.

Ayantunde A, Parsons S . Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007; 18(5):945-9. DOI: 10.1093/annonc/mdl499. View

18.

Emons G, Grundker C, Gunthert A, Westphalen S, Kavanagh J, Verschraegen C . GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer. 2003; 10(2):291-9. DOI: 10.1677/erc.0.0100291. View

19.

Geiger B . Cytoskeleton-associated cell contacts. Curr Opin Cell Biol. 1989; 1(1):103-9. DOI: 10.1016/s0955-0674(89)80045-6. View

20.

Cannistra S, Kansas G, Niloff J, DeFranzo B, Kim Y, Ottensmeier C . Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 1993; 53(16):3830-8. View